Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T
Status:
Unknown status
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
This randomized phase II/III trial investigates the antileukemic activity and toxicity of the
FLAG-Ida regimen as a second induction course in patients with acute myeloid leukaemia and
bad response to the first induction cycle and/or with a high risk karyotype and compares the
antileukemic activity and toxicity of high dose cytarabine/daunorubicin vs. autologous
peripheral blood stem cell transplantation as late consolidation therapy in standard risk
patients.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Hannover Medical School
Collaborators:
Ev. Krankenhaus Essen-Werden Humboldt-Universität zu Berlin Johann Wolfgang Goethe University Hospital Klinikum Augsburg Klinikum Hanover-Siloah Hospital Klinikum Wuppertal GmbH Medizinische Universitätsklinik Tübingen Universitätsklinikum Hamburg-Eppendorf University Hospital Augsburg University Hospital Freiburg University Hospital, Ghent University of Ulm